Science job of the week: 03/03/2016

Here is our science job of the week a Quality Assurance Officer role. This has been chosen as it is:

  • An exciting new role to join a formulation and analytical development services department for a global contract development and manufacturing organisation company.
  • Centrally located in the Midlands with easy access to the M1.
  • Competitive salary – £50,000 – £60,000 with very good benefits.
  • Looking for an excellent candidate with strong experience within chemicals from a sales and marketing perspective.
  • The main purpose of this role is to assess and improve the quality system and contribute to GMP compliance and quality operations associated with the development and manufacture of pharmaceutical products for human use.

Find out more about this job QA here

Posted in Job of the Week, NewsTagged in , , , , , ,

Latest Science Jobs 23.7.2012

Here’s a list of the latest science jobs which CK Science is recruiting for in the UK. Please click on the links below to find out more and apply.

 

Biotechnology Jobs

Pharmaceutical Jobs

Laboratory Jobs

Latest Science Jobs from CK Science

Biochemistry Jobs

Fast Moving Consumer Goods Jobs

Latest Science Jobs from CK ScienceEnvironmental Science Jobs

Production Jobs

Latest Science Jobs from CK Science

Chemical Jobs

Latest Science Jobs from CK ScienceEngineering Jobs

Analytical Chemistry Jobs

Latest Science Jobs from CK Science

Medical Devices Jobs

 

Science Jobs - CK ScienceRegulatory Affairs Jobs

 

 

Posted in Jobs, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , , ,

Votrient gets positive opinion from Euro CHMP

PharmPro reported that GlaxoSmithKline has announced that its Votrient (pazopanib) drug has been issued with a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Votrient® (pazopanib) will be used in the  treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

As part of its assessment, the CHMP reviewed safety and efficacy data from clinical studies, including one randomised, double-blind, placebo controlled, multi-centre Phase III study.

This is good news for those who have selective subtypes of advanced Soft Tissue Sarcoma.

Are you looking for a new science job? Click here to search our jobs in science now.

Follow us on Twitter @CKScienceJobs to receive more industry news and CK jobs of the week updates

 

Posted in Industry News, NewsTagged in , , , , , , , , , , , ,

NIH works with Pfizer, AstraZeneca and Eli Lilly

NIH collaborate with Pfizer, AstraZeneca and Eli LillyFierce Biotech reported that The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.

NIH’s new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly. The drug companies will offer up their data and investigators will have a chance to explore new uses, with a set of deal templates in place to help speed the process on 20 programs.

The investigators will have access to failed drugs to see if they can be repurposed for new uses.

Rod MacKenzie, group senior vice president, head of Pfizer PharmaTherapeutics Research and Development said “Pfizer has a rich history of partnering with the academic and public sectors to discover and develop innovative medicines…We believe that participating in this unique program, and making well researched molecules available to NIH’s broad network of researchers, is another important step in advancing a vibrant biomedical ecosystem.”

Are you looking for a new job in the pharmaceutical industry? Click here to see our latest pharmaceutical jobs in the UK

Follow us on Twitter @CKScienceJobs to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , , , , ,

Sanofi plans to cut R&D jobs

As reported by Business Week, the French Pharma company, Sanofi may be cutting US and EU science jobs.

The news comes as a result of a reorganisation of their R&D operations following their acquisition of Genzyme, as well as the loss of exclusivity on key drugs.

Sanofi plans to group their R&D into four ‘research hubs’ to be based in the US (Boston). France, Germany and Asia. It is hoped that this move will help to improve communication between teams and help integrate R&D operations.

As a result, both sales and R&D jobs will be cut, however, there is no news yet as to exactly how many jobs will be cut.

Like other pharmaceutical companies, in recent times, Sanofi has been taking strides to cut back staff in more mature markets (e.g. Europe and US) and is concentrating on strengthening it’s workforce in emerging markets. In fact, since 2008, Sanofi has created more that 3,700 jobs in these countries.

This news comes just as The Wall Street Journal, reports a 26 per cent rise in Sanofi’s third quarter profit which was boosted by sales in emerging markets.

Are you looking for a job in R&D? Click here to search our current research and development jobs now.

 

Posted in NewsTagged in , , , , , , , ,

Amnis Bought Out by Division of Merck

EMD Millipore, the life sciences arm of pharmaceutical company Merck, has purchased cell imaging instrument manufacturer Amnis Corporation, reports inpharm.com.

Jonathan DiVincenzo, head of life sciences at EMD, has said that the deal improves the company’s flow cytometry range and will create “tremendous value for our customers’ research outcomes.” Amnis’ products are used in flow cytometry applications across various fields including biotech and pharmaceutical cell analysis.

DiVincenzo went on to add that “with this acquisition, EMD Millipore becomes the only provider of this technology.” David Basiji, Amnis chief executive, believes becoming park of Merck will “accelerate product development”for his company. The deal is expected to go through in the final quarter of this year.

Looking for a job in the science industry? Start by clicking here, now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , , , , ,

QinetiQ Sells Fuel Business to Intertek

The QinetiQ Group, based in Farnborough, is selling off its fuel and lubricants business for £500,000, reports insidermedia.com.

The Intertek Group is to take over the UK Fuel and Lubricants Testing Business (OALTB), which QinetiQ has sold in order to concentrate on their core services, including aerospace and security. Intertek is going to bring the fuel business into the pharmaceutical and chemical division of their operations.

This is the third recent acquisition by Intertek, who have also purchased Stoke based Food Analytical Laboratories Limited (FAL) and Rechere Developpement and Consulting (RDC), based in Brussels. Wolfhart Hauser, CEO of Intertek, has said the purchases “demonstrate Intertek’s progress in its strategy to add new expertise and capabilities across the supply chain.” He later commented that the firm is looking forward “to welcoming these companies and their management teams to Intertek.”

Looking for a job in the science industry? Start by clicking here, now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , , , , , , , ,

GSK to Profit From Sale of Non-Core Assets

At least three private equity firms are planning a bid for GSK non-prescription drugs, reports Reuters.

The products being bid for include over the counter painkillers and vitamin supplements. These sales are the product of GSK’s reduction of non-core products announced in February, representing 10% of the consumer healthcare business. Bids for the products are expected on 8th August, but will be negotiable. CEO Andrew Witty expects the deals to close in the fourth quarter of 2011 before adding that GSK will be looking for the best deal for shareholders to benefit.

Rival companies are unlikely to bid for all the products GSK is looking to offload, worth a maximum of around £2 billion. However because the products will not be sold as a single body, analysts believe that GSK will not be able to make that amount. The lack of coherence in the products on sale, other than, as one analyst says “stuff that GSK doesn’t want,” also means it will be difficult to sell the portfolio for such an amount in one go.

Looking for a job in the science industry? Start by clicking here, now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , ,

GSK in Job and Tax Pledge

GlaxoSmithKline is set to create more UK jobs and pay more tax, helping the economy, reports the Guardian.

As CK Science has earlier reported, here, GSK is set to expand its UK operations, adding to the current 16,000 employees throughout Britain. Two sites in Scotland and one in county Durham are being looked into as locations to create new plants. This comes at a time when other companies with UK branches are scaling back their operations. Andrew Witty, GSK’s chief executive, has said that his company wants to “have more manufacturing and do more R&D work in Britain” leading to a greater amount of tax paid by GSK.

In the next few years, GSK expects to be a “net hirer” because the UK can strike a good balance between research and development support and competitive medicine prices. GSK has moved back into the black this year, recording a £1.1 billion profit in the second quarter, meaning that they can afford the expense of reopening UK operations.

Looking for a job in the science industry? Start by clicking here, now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , , ,

Quintiles to Create UK Jobs

Biopharmaceutical company Quintiles is looking to establish more UK sites, creating pharmaceutical and clinical jobs, reports pharmatimes.com.

The US company sees the UK as a good place for clinical trials and is hoping to open at least two more Prime Sites to go alongside the one at Queen Mary, University of London. Including two other current sites, Quintiles employs 2,000 people in the UK, a figure set to rise with the planned opening of the new Prime Sites.

Lindy Jones, Quintiles head of global integrated site services, says the UK is of “significant interested to us,” with fifty trials currently being run at the Queen Mary site. Jones believe that the UK “has opened up far more to clinical research” in the past eighteen months, meaning that Quintiles is considering opening “an additional two, maybe three Prime Sites in the UK.”

Looking for a job in the science industry? Start by clicking here, now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , , , ,

TryggPharma Re-opens Teeside Pharma Plant

TryggPharma of Norway is set to re-open a former Lundbeck Pharmaceuticals site in Seal Sands, creating 25 new pharmaceutical jobs, reports peterleemail.com.

A £14 million deal has been agreed in which Lundbeck will sell their site, which they closed during the recession. TryggPharma’s vice president of engineering Peter Harper has said the company is “very impressed with the facility [as it has] easy to access from Norway, Europe and our customers around the world”.

The facility is expected to employ 25 people within 12 months and the company has said there is a “commitment to invest and expand into the future of Teeside”. The North East Process Industry Cluster chief executive Stan Higgins has said the re-opening of the site is “great news for Teeside and for the pharmaceutical sector in particular”.

Looking for a job in science? Start by clicking here now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , ,

Senior Protein Scientist LCMS Role – Berkshire

We are currently recruiting for a “Pharmaceutical” Senior Scientist in Protein Chemistry LC-MS to join a Pharmaceutical Laboratory based a commutable distance from London in Berkshire, which performs a wide range of analytical contracts for a variety of pharmaceutical and healthcare companies.

Responsibilities:

As a Senior Protein Scientist LCMS the ideal candidate will lead and perform a range of routine and investigative analyses applying their expertise in the MS analysis of proteins, peptides and PTMs, whilst working to GMP quality standards.

The role of Senior Scientist is to undertake a combined supervisory and practical role within defined business areas of the Biotech sector.  They will be working in a cross functional role in the Biotech sector which spans the Pharmaceutical laboratory, DNA and Protein laboratory and others but be based in the Pharmaceutical laboratory.  They will be expected to play a key role in ensuring that delegated projects are managed effectively and that the customer’s requirements and contractual agreement are fulfilled in a timely manner.

They will contribute to the pharmaceutical business through leading and growing the LC-MS protein chemistry area by application of your expert knowledge whilst working to GMP quality standards.  The role will involve performing, checking, supervising and training in your area of expertise in a range of routine and specialised analyses.

Person Specification:

The ideal candidate for this Senior Protein Scientist LCMS role will be educated to degree level in a relevant scientific discipline (or equivalent) and will have an in depth understanding of protein structure-function and glycan structures. They will have demonstrable relevant laboratory experience in protein and glycoprotein analysis by MS including amino acid sequence analysis, peptide mapping, glycan characterisation and identification of other post-translational modifications. They will also have experience in discovery, development and/or structural elucidation of proteins.

Strong project management skills (including project plans, updates, flagging problems on time, etc) will be required as will a flexibility and adaptability to meet customer/business requirements. They will be well organised with the capability of working on multiple activities concurrently and will have meticulous attention to detail. Experience of working to GMP is highly desirable.

Apply now:

For more information or to apply for this Senior Protein Scientist LCMS role, please contact Jason Johal on 01438 723 500 or jjohal@ckscience.co.uk. Please quote reference ST22219 in all correspondence.

                                                           Click here to apply online!

Posted in Jobs, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , ,

Associate Director Job (Pharmaceuticals, Quality Auditing) – Suffolk, UK

We are currently looking for an Associate Director to join a global pharmaceutical company in the Suffolk region.

As Associate Director, you will be responsible for developing and managing audit programs for healthcare compliance and privacy at the company’s facilities to ensure they are meeting the relevant company and regulatory standards.

 

As Associate Director, you will also:

  • Develop and introduce a process for carrying out healthcare compliance audits. This will include the auditing procedure and the reporting of audit results and metrics to senior management.
  • Train company auditors in healthcare compliance auditing.
  • Auditing company facilities including country offices and relevant business units for healthcare compliance.
  • Develop and introduce a process for carrying out privacy audits. This will include the auditing procedure and the reporting of audit results and metrics to senior management.  The audits will check that the organization can both meet the requirements of the company and the relevant regulatory requirements.
  • Train auditors in privacy auditing.
  • Auditing facilities for privacy.

 

Person specification:

The ideal candidate for this Associate Director position will have the following qualifications, skills and experience:

  • Possess a Bachelors degree (or equivalent) with related industry experience.
  • Extensive experience in auditing
  • Expert knowledge of healthcare compliance and/or privacy requirements for the pharmaceutical and/or medical device industries
  • Strong written and oral communication skills.

 

How to apply

For more information or to apply for this Associate Director position, please contact Jason Johal at CK Science on 01438 723 500 or email jjohal@ckscience.co.uk. Please quote reference ST22200 in all correspondence.

 

Click here to apply online!

Not quite what you’re looking for? Search our current pharmaceutical jobs online now.

Posted in JobsTagged in , , , , , , , , , , , , , ,

Our best Pharma & Biotech candidates…

The Consultants here at CK Science are currently helping some excellent candidates who are looking for new positions in the Pharmaceutical and Biotechnology Industries.

Please click on the links below to find out more about candidates currently based in your area:

South, UK

  • Assay/Cell Culture Scientist
  • Research Scientist
  • NPD Scientist
  • Method Development Scientist
  • Senior Microbiologist
  • QA Specialist
  • Formulations Chemist
  • Product/Manufacturing Technician

 

Midlands, UK

  • Validation Scientist
  • Pharmaceutical Analyst
  • Senior Laboratory Technician
  • QC Analyst

 

North, UK

  • QC Manager
  • GMP Technician
  • Senior Supervisor
  • Graduate Analyst
Posted in CandidatesTagged in , , , , , , , , , , , , , , , , , , , , , ,

Pharma Company buys Scottish Chemicals Plant

As reported by the BBC News, the pharmaceutical company, Bakhu Pharma have acquired the chemical plant, Phoenix Chemicals in a deal which could create 50 jobs within 12 months.

Bakhu Pharma is the third owners of the plant in three years and speaking of the deal, their chief executive stated,

“This was a last-minute rescue plan that was put together very quickly,” said Mr Leece.

“Annan was about to be decommissioned but thanks to a huge effort by a few people, we have rescued the business from the ashes.”

The Merseyside-based Phoenix Chemicals originally bought the plant with the help of a grant from the Scottish government of £400,000. However, the company went into administration in January 2011.

Are you looking for a new job in science? Click here to search our current science jobs online now.

Posted in Industry NewsTagged in , , , , , , , , , , , ,

Slow Sales for Boots in UK Stores

As reported by The Guardian, Boots has experienced a disappointing 1.7% increase in like-for-like sales in the UK, whilst their international parent company, Alliance Boots, recorded a bumper increase of 15.1%.

Executive chairman, Stefano Pessina thinks the tough conditions are likely to continue, and stated: “Looking to the year ahead, we are planning for consumer demand to be subdued and expect governments to continue to seek ways to contain growth in healthcare expenditure.”

Pessina also stared that as a group they will continue to focus their efforts on international expansion this year despite the challenging market conditions.

Click here to search our pharmaceutical jobs online now!

Posted in Industry NewsTagged in , , , , , ,

Senior Protein Scientist Job – Berkshire, UK

We are currently recruiting for a Senior Protein Scientist to join a pharmaceutical laboratory based in Berkshire that performs a wide range of analytical contracts for a variety of pharmaceutical and healthcare companies.

In this Senior Protein Scientist role you will contribute to this through leading and performing a range of routine and investigative analyses applying your expertise in the MS analysis of proteins, peptides and PTMs, whilst working to GMP quality standards. 

Roles and Responsibilities:

As Senior Protein Scientist, you will have the following roles and responsibilities:

  • You will undertake a combined supervisory and practical role within defined business areas of the Biotech sector.
  • You will be working in a cross functional role in the Biotech sector which spans the Pharmaceutical laboratory, DNA and Protein laboratory but based in the Pharmaceutical laboratory.
  • You will be expected to play a key role in ensuring that delegated projects are managed effectively and that the customer’s requirements and contractual agreement are fulfilled in a timely manner.

 

Requirements:

The ideal candidate for this Protein Scientist position will have the following skills, knowledge and experience:

  • The ability to undertake a range of routine and investigative analyses including sample preparation and interpretation of results, primarily by MS but may also include other classical protein chemistry techniques.
  • The ability provide high quality customer service by ensuring effective workflow within the assigned area of responsibility, integrity of analytical data generated and timely/accurate provision of results.
  • The ability to manage client queries, produce accurate quotations and ensure client’s expectations are achieved.
  • You will be well organised and capable of working on multiple activities concurrently and will have meticulous attention to detail.
  • You will also have the ability to take responsibility for projects and the ability to be able to discuss, problem solve/troubleshoot clients’ specific needs and deal with client queries as appropriate.
  • Educated Degree level in a relevant scientific discipline (or equivalent) and will have an in-depth understanding of protein structure-function and glycan structures and experience in discovery, development and/or structural elucidation of proteins.
  • Demonstrable relevant laboratory experience in protein and glycoprotein analysis by MS including amino acid sequence analysis, peptide mapping, glycan characterisation and identification of other post-translational modifications is essential.
  • Demonstrable relevant laboratory experience in proteomics or metabolomics analysis using mass spectrometry is highly desirable as is experience of working to GMP.

 

How to apply:

For more information, or to apply for this Senior Protein Scientist position, please contact Jason Johal at CK Science on 01438 723 500 or email jjohal@ckscience.co.uk. Please quote reference ST21861 in all correspondence.

Apply online:

Click here to apply for this Senior Protein Scientist job now.

Posted in JobsTagged in , , , , , , , , , , , , ,

Novartis to Cut UK Pharmaceutical Jobs

As reported by the BBC, The Swiss-based pharmaceutical company, Novartis are reportedly planning to close their drug development and manufacturing operations in Horsham, West Sussex, leading to  hundreds of cuts to pharmaceutical jobs.

This site currently employees 950 staff and this is set to reduce to 400 within just two years. It produces approximately 60 different formulations of drugs. Staff will be retained who work on developing respiratory drugs in Horsham. Those focused on gastrointestinal medicines will be relocated to their units based in Cambridge, Massachusetts and Basel in Switzerland.

The announcement comes after a series of cuts by pharmaceutical companies across the UK. Including, Pfizer who are to close their research and development centre in Sandwich, Kent – potentially cutting up to 2,400 posts. In addition, both AstraZeneca and GlaxoSmithKline are shutting down sites across the UK.

Novartis have disputed the notion that their plans to close the Horsham site is linked to the decline in attractiveness of the UK in terms of innovation. General Manager, Sue Webb stated, “With significant changes in healthcare systems aimed to contain or cut cost, this critical assessment and the subsequent potential changes to the Novartis UK organisation are key to maintain significant investment in innovative drugs and our research efforts in the UK.”

The Swiss-based pharmaceutical company plan to maintain their manufacturing sites based in Grimsby, Liverpool and Dundee.

Are you looking for a new position in the UK Pharmaceutical Industry? Click here to search our current jobs now.

Posted in Industry NewsTagged in , , , , , , , , , , , , , , , , ,